CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Belotaxel +1 moredrug
Likely dose
Belotaxel 60 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01243775
NCT01243775Phase 2Completed
CompareCT.gov

Phase II Trial of First Line Docetaxel and Oxaliplatin in Stage IV or Relapsed Non-Small Cell Lung Cancer

Chonnam National University Hospital·interventional·Posted Nov 19, 2010·Updated Aug 17, 2015

In Brief

A Phase 2 clinical trial evaluating Belotaxel and Belloxa for Non-Small Cell Lung Cancer. Completed, enrolled 33 participants across 1 site.

Detailed Summary

Lung cancer is the leading cause of cancer death in Korea as well as in other countries. About 80% of lung cancer is non-small cell lung cancer(NSCLC). The majority of patients with NSCLC require cytotoxic chemotherapy in the course of their illness. Combination chemotherapy using third generation anticancer drugs (paclitaxel, docetaxel, gemcitabine) with platinums(cisplatin or carboplatin) reached a plateau in their efficacy. Oxaliplatin, another platinum being used for colorectal, gastric and pancreatic cancer has lower adverse effects such as nausea and nephrotoxicity. In this phase II trial, we will observe efficacy and safety of docetaxel and oxaliplatin for patients with NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesSouth Korea
CollaboratorsChong Kun Dang Pharmaceutical

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 19, 2010
Enrollment StartNov 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.6 years ago

Interventions

Belotaxeldrug

60 mg/m2 3 weekly (day 1)

Belloxadrug

70 mg/m2 3 weekly (day 2)